Lead identification is the drug‑discovery stage where researchers narrow a large pool of “hits” down to a smaller set of promising compounds, called leads, that merit deeper optimisation. It balances potency, selectivity, and basic safety properties. For healthcare stakeholders, this term matters because AI platforms often promise to speed up or improve lead identification, potentially influencing which disease targets progress into expensive development.